Dr. Daniel De Carvalho is the scientific co-founder at Adela. Daniel is a world-leader in cancer epigenomics research and since 2012 has led a research group at the Princess Margaret Cancer Centre and the University of Toronto. He is pioneering the use of cancer epigenetics combined with advanced computational approaches for developing novel diagnostic tools and applications. Daniel holds a PhD from the University of Sao Paulo, Brazil and completed his postdoctoral training under the supervision of the pioneer in DNA methylation, Dr. Peter Jones, at the University of Southern California.
Daniel has published over 65 high profile research papers, many of those featured in prestigious scientific journals such as Nature, Science, Cell, Nature Medicine, and Cancer Cell, and was an invited speaker to over 120 talks worldwide, including prestigious venues such as the Opening plenary lecture at AACR annual meeting. For his scientific contributions, Daniel has received numerous awards including the AACR-Waun Ki Hong Award, Canadian Cancer Society Bernard and Francine Dorval Prize and the Canadian Institutes of Health Research (CIHR) Early Career Award in Cancer. He also received the Canada Research Chair in Cancer Epigenetics, the Helen M Cooke Endowed Professorship and was elected membership in the 2019 cohort of The Royal Society of Canada.
April, 2021 - present
EVP, Research & Development & Chief Scientific Officer at AbbVie
Chief Scientific Officer at Rhythm AI
President Of Research & Development And Chief Scientific Officer at Karuna Therapeutics
Chief Scientific Officer at Calico
Chief Scientific Officer at Alltrna
Access the worlds's biggest network of public org charts
Learn more